



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/230,111	05/17/1999	TAKA-AKI SATO	48962-A-PCT-	4836

7590

02/26/2003

JOHN P WHITE
COOPER & DUNHAM
1185 AVENUE OF THE AMERICAS
NEW YORK, NY 10036

EXAMINER

HOLLERAN, ANNE L

ART UNIT

PAPER NUMBER

1642

27

DATE MAILED: 02/26/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.

09/230,111

Applicant(s)

SATO ET AL.

Examiner

Anne Holleran

Art Unit

1642

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 18 December 2002 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

PERIOD FOR REPLY [check either a) or b)]

- a) ☐ The period for reply expires _____ months from the mailing date of the final rejection.
- b) ☐ The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. **ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).**

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

1. ☐ A Notice of Appeal was filed on _____. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.
2. ☐ The proposed amendment(s) will not be entered because:
- (a) ☐ they raise new issues that would require further consideration and/or search (see NOTE below);
 - (b) ☐ they raise the issue of new matter (see Note below);
 - (c) ☐ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
 - (d) ☐ they present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: _____.

3. ☐ Applicant's reply has overcome the following rejection(s): _____.
4. ☐ Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☒ request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.
6. ☐ The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.
7. ☐ For purposes of Appeal, the proposed amendment(s) a) ☐ will not be entered or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: _____.

Claim(s) objected to: _____.

Claim(s) rejected: _____.

Claim(s) withdrawn from consideration: _____.

8. ☐ The proposed drawing correction filed on _____ is a) ☐ approved or b) ☐ disapproved by the Examiner.
9. ☐ Note the attached Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____.
10. ☒ Other: See Continuation Sheet

Continuation of 5. does NOT place the application in condition for allowance because: applicant's arguments are not persuasive. The rejection of claims 121-141 under 112, second paragraph is maintained because the specification fails to teach peptides that "consist essentially of" the sequences that are set forth in the claims. Instead, the specification teaches proteins that comprise the sequences and peptides that consist of the sequences. In the case of claims to polypeptide products, the phrase "consisting essentially of" a particular sequence does not have different scope from the phrase "comprising" a particular sequence, unless the specification specifically defines what the phrase "consisting essentially of" means relative to a particular sequence. The specification does not contain such a disclosure, and it is not clear how many amino acids may be added to or removed from the recited sequences, where the removal or addition would result in a peptide that consisted essentially of a peptide with the recited sequence.

The rejection of 121-141 under 112, first paragraph, for lack of enablement for the full scope of the claimed invention, is maintained for the reasons of record.

The rejection of claims 121-132 and 139-141 under 112, first paragraph, because the amendments to the claims introduce new matter into the specification is maintained for the reasons of record.

The rejection of claims 121-132 and 139-141 under 102(e) is maintained for the reasons of record. Applicant argues that the claims should not be interpreted as encompassing methods where the signal transducing protein is a Fas receptor, because of the use of "consisting essentially of" to describe the sequence of the polypeptide. As discussed above, in the case of polypeptides, the phrase "~~consisting of~~" has the same scope as the phrase "comprising". Therefore, Reed discloses the claimed methods.

Att
9/24/03
"consisting essentially of"

Continuation of 10. Other: The IDS filed August 15, 2002, will be placed in the file, but not considered, because it was filed after the mailing date of a final Office action, and does not comply with 1.97(d)..